-
1 week ago | 
nature.com | Alex Bataller |Hannah Goulart |Ghayas C. Issa |Courtney DiNardo |Tapan M Kadia |Ian Bouligny | +12 more
AbstractAcute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar) has poor outcomes. We analyzed 1,611 patients with AML and 4.3% demonstrated rearrangements in KMT2A. Signaling-related genes (NRAS 30%, KRAS 23% and FLT3-TKD 16%) were the most frequently mutated in patients with KMT2Ar AML.
-
1 month ago | 
nature.com | Jayastu Senapati |Guillermo Garcia-Manero |Courtney DiNardo |Gautam Borthakur |Tapan M Kadia |Elias Jabbour | +8 more
Despite the improvement in overall outcomes of patients with acute myeloid leukemia (AML), some high-risk disease subsets continue to fare dismally. AML with TP53 aberrations (mutations, deletions) is one such subset of high-risk AML with a median survival of about 6–9 months [1,2,3].
-
2 months ago | 
nature.com | Courtney DiNardo |Wei-Ying Jen |Koichi Takahashi |Tapan M Kadia |Sanam Loghavi |Patrick K. Reville | +19 more
AbstractIntensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report the long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in combination with venetoclax.
-
Feb 9, 2025 | 
onlinelibrary.wiley.com | Jayastu Senapati |Sanam Loghavi |Jennifer Marvin-Peek |Guillermo Garcia-Manero
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description ajh27628-sup-0001-supinfo.docxWord 2007 document , 8.8 MB Data S1. Supporting Information. References 1, , , et al., “Genomic Classification and Prognosis in Acute Myeloid Leukemia,” New England Journal of Medicine 374, no. 23 (2016): 2209–2221, https://doi.org/10.1056/NEJMoa1516192.
-
Nov 13, 2024 | 
nature.com | Vera Adema |Kelly S. Chien |Sanam Loghavi |Feiyang Ma |Guillermo Montalban-Bravo |Xuelin Huang | +1 more
AbstractIn myelodysplastic syndromes (MDS), the IL-1β pathway is upregulated, and previous studies using mouse models of founder MDS mutations demonstrated that it enhances hematopoietic stem and progenitor cells’ (HSPCs’) aberrant differentiation towards the myeloid lineage at the expense of erythropoiesis.
-
Nov 13, 2024 | nature.com | Vera Adema |Kelly S. Chien |Sanam Loghavi |Feiyang Ma |Guillermo Montalban-Bravo |Xuelin Huang | +1 more
AbstractIn myelodysplastic syndromes (MDS), the IL-1β pathway is upregulated, and previous studies using mouse models of founder MDS mutations demonstrated that it enhances hematopoietic stem and progenitor cells’ (HSPCs’) aberrant differentiation towards the myeloid lineage at the expense of erythropoiesis.
-
Aug 12, 2024 | 
oncodaily.com | Sanam Loghavi
Sanam Loghavi shared a post by Rahul Banerjee, Assistant Professor at UW Medicine, on X:“Have never been as honored and flattered. The feeling and respect is mutual. It’s been a joy and honor to take part in this amazing project.
-
Mar 18, 2024 | 
nature.com | Feiyang Ma |Kelly S. Chien |Sanam Loghavi |Guillermo Montalban-Bravo |Vera Adema |Rashmi Kanagal-Shamanna | +2 more
AbstractThe molecular mechanisms of venetoclax-based therapy failure in patients with acute myeloid leukemia were recently clarified, but the mechanisms by which patients with myelodysplastic syndromes (MDS) acquire secondary resistance to venetoclax after an initial response remain to be elucidated.
-
Dec 8, 2023 | 
newsbreak.com | Sanam Loghavi
By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
-
Dec 8, 2023 | 
targetedonc.com | Sanam Loghavi
December 8, 2023Targeted Therapies in OncologyDecember I, 2023Pages: 58The required blast threshold of 20% has now been omitted from AML with defining genetic abnormalities with the exception of AML with BCR::ABL1 and AML with CEBPA mutation. Major updates and revisions for acute monocytic leukemia (AML) based on the World Health Organization (WHO) Classification of Haematolymphoid Tumours, 5th edition, (5th ed)1 include increased emphasis on genetic and molecular drivers of disease.
